

# Neuroprotective Products: World Market Prospects 2012-2022

<https://marketpublishers.com/r/N0C4705368BEN.html>

Date: May 2012

Pages: 117

Price: US\$ 2,635.00 (Single User License)

ID: N0C4705368BEN

## Abstracts

### Your guide to trends and revenue prospects in neuroprotection

What are the commercial prospects for neuroprotective treatments? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and outlooks.

Many neuroprotective products are in development. Our study lets you assess projected sales at overall world market, therapeutic submarket and product level to 2022.

The protection of nerve tissues is becoming more important. You can assess the potential for drug revenues there, as well as finding discussions of stem cells and gene therapy.

In particular, how will 11 products - including Rasagiline, Minocycline, Memantine and NeuroSTAT - perform to 2022? Our investigation gives you business research and analysis with sales forecasts.

You also see forecasting of five world-level submarkets to 2022, finding potential revenues:

Ion channel modulators

Mitochondrial dysfunction regulators

Anti-inflammatory and anti-apoptotic agents

Neurotrophic factors

Other neuroprotective treatments.

Our study lets you assess the R&D pipeline, seeing trends and prospects. You find data and discussions on developmental topics:

Alzheimer's disease

Parkinson's disease

Multiple sclerosis

Brain injury

Ocular degeneration (retinal disorders)

Huntington's disease

Amyotrophic lateral sclerosis (ALS)

Neuropathies

Other disorders affecting the nervous system.

The neuroprotection market offers strong opportunities for medicines to slow disease progression, protecting the central nervous system (CNS). Our report shows and explains.

### **Market value for 2014 and outlook for the future**

What does the future hold? The pharma industry will develop more drugs for neuronal protection, with high revenues possible this decade and beyond. The R&D pipeline is strong and promising. Overall world revenues will reach \$2.6bn in 2014, our report forecasts.

We predict that the neuroprotection market will achieve strong revenue growth to 2022, especially from 2017. By then, many clinical trials will have finished and products will gain regulatory approval. You see prospects for novel drugs.

Rising incidence and prevalence of neurodegenerative diseases in ageing populations will stimulate that treatment market. Also stimulating the industry and market will be the treatment of brain injuries, especially those from traffic accidents.

What are companies doing? Our work discusses Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and others, evaluating commercial prospects. The scope of the field is widening, with many organisations entering and collaborating.

The aim of drug developers is to prevent neuronal death and revive damaged neurons (neuroregeneration). However, not all neuroprotective agents will be neuroregenerative, the study predicts.

Regulatory agencies recognise the therapeutic potential of neuroprotective agents and have given fast track designation and orphan drug status to candidates.

You can investigate the future of neuroprotection now, discovering revenue potential and other prospects.

### **Sales forecasts, market shares, developmental trends and discussions**

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 46 tables, 22 charts and two research interviews.

### **Nine ways Neuroprotective Products: World Market Prospects 2012-2022 helps you**

In particular, our study gives you the following knowledge on the topic:

Find potential revenues to 2022 for the world market and submarkets

Discover projected revenue trends of 11 leading products to 2022

See predictions of launch times for prominent drug candidates

Assess 7 leading companies, and other players, discovering activities and outlooks

Review R&D pipelines, seeing trends by therapeutic area and organisation

Investigate competition and opportunities influencing sales

Find out what will stimulate and restrain the industry and market

Analyse prospects for established companies and those seeking to enter the sector

View opinions from our survey, seeing interviews with authorities in industry.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Without our report you could miss out on information that your competitors use.

### **Gain research and analysis now for neuroprotective treatments**

Our study is for everybody needing industry and market analyses for neuroprotection. You find data, predictions and answers there. Please order that report now.

Visiongain is a trading partner with the US Federal Government  
CCR Ref number: KD4R6

## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Overview of Findings
- 1.2 Structure of the Report
- 1.3 Research and Analysis Methods
- 1.4 Scope of the Report
  - 1.4.1 Inclusions
  - 1.4.2 Exclusions

### **2. INTRODUCTION TO NEUROPROTECTION**

- 2.1 What is Neuroprotection?
- 2.2 History of Neuroprotective Agents
- 2.3 Neurodegeneration
  - 2.3.1 Excitotoxicity
  - 2.3.2 Oxidative Stress
- 2.4 Mechanisms of Neuroprotection
  - 2.4.1 Ion Channel Modulators
  - 2.4.2 Mitochondrial Dysfunction Regulators
  - 2.4.3 Anti-inflammatory and Anti-apoptotic Agents
  - 2.4.4 Neurotrophic Factors
  - 2.4.5 Other Neuroprotective Agents
- 2.5 Importance of Neuroprotective Agents

### **3. WORLD MARKET FOR NEUROPROTECTIVE AGENTS TO 2022**

- 3.1 Neuroprotective Agents: World Market, 2011
- 3.2 Neuroprotective Agents: World Market Forecast, 2012-2022
- 3.3 Classes of Neuroprotective Agent
  - 3.3.1 Ion Channel Modulators
    - 3.3.1.1 Ion Channel Modulators: Market Forecast, 2011-2012
  - 3.3.2 Mitochondrial Dysfunction Regulators
    - 3.3.2.1 Mitochondrial Dysfunction Regulators: Market Forecast, 2012-2022
  - 3.3.3 Anti-inflammatory and Anti-apoptotic Agents
    - 3.3.3.1 Anti-inflammatory and Anti-apoptotic Agents: Market Forecast, 2012-2022
  - 3.3.4 Neurotrophic Factors
    - 3.3.4.1 Neurotrophic Factors: Market Forecast, 2012-2022

### 3.3.5 Other Neuroprotective Agents

#### 3.3.5.1 Other Neuroprotective Agents: Market Forecast, 2012-2022

## 4. PROMINENT NEUROPROTECTIVE AGENTS UNDER DEVELOPMENT

### 4.1 Rasagiline (Teva/Lundbeck)

#### 4.1.1 Rasagiline is Currently Approved for Parkinson's Disease

#### 4.1.2 Rasagiline as a Neuroprotectant

#### 4.1.3 Rasagiline: Market Potential Analysis, 2012-2022

#### 4.1.4 Competition for Rasagiline

### 4.2 Minocycline (National Institute of Neurological Disorders and Stroke [NINDS])

#### 4.2.1 Minocycline: Competitor Analysis and Sales Forecast, 2012-2022

### 4.3 Memantine (Merz/Lundbeck/Forest Laboratories/Daiichi Sankyo)

#### 4.3.1 Memantine: Competitor Analysis and Sales Forecast, 2012-2022

### 4.4 NeuroSTAT (NeuroVive Pharmaceutical AB)

#### 4.4.1 NeuroSTAT: Competitor Analysis and Sales Forecast, 2012-2022

### 4.5 Erythropoietin (Various Companies)

#### 4.5.1 EPO: Competitor Analysis and Sales Forecast, 2012-2022

### 4.6 GM6 (Genervon Biopharmaceuticals)

#### 4.6.1 Current Status of Development

#### 4.6.2 GM6 Sales Forecast, 2012-2022

#### 4.6.3 GM6: Competitors and Risk Analysis

### 4.7 NNZ-2566 (Neuren Pharmaceuticals)

#### 4.7.1 NNZ-2566: Competitor Analysis and Sales Forecast, 2012-2022

### 4.8 Progesterone (BHR-100, BHR Pharma LLC)

#### 4.8.1 Progesterone: Competitor Analysis and Sales Forecast, 2012-2022

### 4.9 Davunetide (Allon Therapeutics)

#### 4.9.1 Davunetide: Competitor Analysis and Sales Forecast, 2012-2022

### 4.10 Laquinimod (Teva/Active Biotech AB)

#### 4.10.1 Laquinimod: Competitor Analysis and Sales Forecast, 2012-2022

### 4.11 CXB909 (Krenitsky Pharmaceuticals/CeNeRx BioPharma)

#### 4.11.1 CXB909: Competitor Analysis and Sales Forecast, 2012-2022

## 5. LEADING ORGANISATIONS IN 2012

### 5.1 Genervon Biopharmaceuticals

#### 5.1.1 Platforms for Drug Discovery and Development

#### 5.1.2 R&D Pipeline Analysis

### 5.2 Neuren Pharmaceuticals

- 5.2.1 Market Position and R&D Pipeline
- 5.2.2 US Army Funding for NNZ-2566
- 5.3 NeuroVive Pharmaceutical AB
  - 5.3.1 Current Status and R&D Pipeline
  - 5.3.2 Strategic Collaborations
- 5.4 Allon Therapeutics
  - 5.4.1 Market Status and R&D Pipeline
- 5.5 Ceregene
  - 5.5.1 Current Status and R&D Pipeline
- 5.6 BHR Pharma
  - 5.6.1 Current Status and R&D Pipeline
- 5.7 Varinell
  - 5.7.1 Current Status and R&D Pipeline
  - 5.7.2 Strategic Collaborations
- 5.8 National Institute of Neurological Disorders and Stroke (NINDS)
  - 5.8.1 Research Supported by NINDS
- 5.9 Leading Countries in Neuroprotective Research

## **6. NEUROPROTECTIVE AGENTS IN VARIOUS PATHOLOGIES**

- 6.1 Brain Injury
  - 6.1.1 Current Treatment for Brain Injuries
  - 6.1.2 Neuroprotective Agents under Development for Brain Injuries
- 6.2 Alzheimer's Disease
  - 6.2.1 Limited Number of Drugs Approved for Alzheimer's
  - 6.2.2 Neuroprotective Agents under Development for Alzheimer's Disease
- 6.3. Parkinson's Disease
  - 6.3.1 Current Therapies for Parkinson's Disease
  - 6.3.2 Neuroprotective Agents under Development for Parkinson's Disease
- 6.4 Multiple Sclerosis
  - 6.4.1 Current Therapies for Multiple Sclerosis
  - 6.4.2 Neuroprotective Agents under Development for Multiple Sclerosis
- 6.5 Ocular Degeneration
  - 6.5.1 Current Treatment for Ocular Degeneration
  - 6.5.2 Neuroprotective Agents under Development for Ocular Degeneration
- 6.6. Other Neurodegenerative Diseases
  - 6.6.1 Huntington's Disease
    - 6.6.1.1 Treatment Options

## 6.6.2 Amyotrophic Lateral Sclerosis (ALS)

### 6.6.2.1 Treatment Options

## 6.6.3 Neuropathies

### 6.6.3.1 Neuropathic Pain

### 6.6.3.2 Treatment Options

## 6.6.4 Neuroprotective Agents under Development for Other Neurodegenerative Diseases

# 7. NEUROPROTECTIVE AGENTS: QUALITATIVE INDUSTRY ANALYSIS

## 7.1 Strengths

### 7.1.1 Neurological Disorders are High Profile

### 7.1.2 Chronic Diseases: Long-Term Repeat Sale

## 7.2 Weaknesses

### 7.2.1 The High Cost of Treatment

### 7.2.2 Difficulty Generating Ideal Laboratory Models for Neuroprotection

### 7.2.3 Difficulty in Clinical Trials for Neuroprotection

## 7.3 Opportunities

### 7.3.1 Orphan Status and Fast-Track Reviews for New Drugs

### 7.3.2 Aging Populations Will Lead to Increased Disease Prevalence

### 7.3.3 Significant Unmet Needs Exist in the Market

## 7.3.4 Alternative Treatments Provide Additional Opportunities to the Neuroprotection Industry

### 7.3.4.1 Stem Cell Therapy

### 7.3.4.2 Gene Therapy

## 7.4 Threats

# 8. RESEARCH INTERVIEWS

## 8.1 Interview with Larry Glass, CEO, Neuren Pharmaceuticals (March 2012)

### 8.1.1 Failure of Clinical Trials Testing Neuroprotective Agents

### 8.1.2 Agent NNZ-2566

### 8.1.3 Sub-classes of Neuroprotective Agent

### 8.1.4 Promising Neuroprotective Agents

### 8.1.5 Potential of Neuroprotective Agents

## 8.2 Interview with Winston Ko, CEO, Genervon Biopharmaceuticals (March 2012)

### 8.2.1 Lack of Approved Neuroprotective Agents

### 8.2.2 Sub-classes of Neuroprotective Agent

### 8.2.3 Agent GM6



8.2.4 Promising Neuroprotective Agents

8.2.5 Potential of Neuroprotective Agents

## **9. CONCLUSIONS**

9.1 High Demand for Neuroprotective Agents in Medicine

9.2 Multibillion Dollar Revenues Possible from World Neuroprotection Market

9.3 Strong R&D Pipeline for Neuroprotective Agents

9.4 Rising Disease Prevalence Levels from Aging Populations Will Drive Market Growth

9.5 Going from Pre-clinical Studies into Clinical Testing Will Remain Challenging

9.6 Concluding Remarks

## List Of Tables

### LIST OF TABLES

Table 3.1 Neuroprotective Agents: Market Forecast by Drug Categories (\$bn), 2011-2022

Table 3.2 Neuroprotective Agents World Market Forecast (\$bn), 2011-2022

Table 3.3 Neuroprotective Agents Drug Class: Sales (\$bn) & Market Shares (%), 2011

Table 3.4 Neuroprotective Agents Drug Class: Sales (\$bn) & Market Shares (%), 2015

Table 3.5 Neuroprotective Agents Drug Class: Sales (\$bn) & Market Shares (%), 2022

Table 3.6 Ion Channel Modulators Sales Forecast (\$bn), 2011-2022

Table 3.7 Mitochondrial Dysfunction Regulators Sales Forecast (\$bn), 2011-2022

Table 3.8 Anti-inflammatory & Anti-apoptotic Agents Forecast (\$bn), 2011-2022

Table 3.9 Neurotrophic Factors Forecast (\$bn), 2011-2022

Table 3.10 Other Neuroprotective Agents Forecast (\$bn), 2011-2022

Table 4.1 Key Neuroprotective Agents: Sales Forecast (\$bn), 2011-2022

Table 4.2 Rasagiline Sales Forecast (\$bn), 2011-2022

Table 4.3 Studies Investigating Minocycline as a Neuroprotectant

Table 4.4 Minocycline Sales Forecast (\$bn), 2011-2022

Table 4.5 Memantine Sales Forecast (\$bn), 2011-2022

Table 4.6 NeuroSTAT Sales Forecast (\$bn), 2011-2022

Table 4.7 Studies Investigating Erythropoietin as a Neuroprotectant, 2012

Table 4.8 Erythropoietin Sales Forecast (\$bn), 2011-2022

Table 4.9 GM6: Preliminary Results, 2012

Table 4.10 GM6 Development, 2012

Table 4.11 GM6 Sales Forecast (\$bn), 2011-2022

Table 4.12 NNZ-2566 Sales Forecast (\$bn), 2011-2022

Table 4.13 Progesterone Sales Forecast (\$bn), 2011-2022

Table 4.14 Davunetide Sales Forecast (\$bn), 2011-2022

Table 4.15 Laquinimod Sales Forecast (\$bn), 2011-2022

Table 4.16 CXB909 Sales Forecast (\$bn), 2011-2022

Table 5.1 Genervon Biopharmaceuticals: R&D Pipeline, 2012

Table 5.2 Neuren Pharmaceuticals: R&D Pipeline, 2012

Table 5.3 NeuroVive Pharmaceutical: R&D Pipeline, 2012

Table 5.4 NeuroVive Pharmaceutical: Strategic Collaborations

Table 5.5 Allon Therapeutics: R&D Pipeline, 2012

Table 5.6 Ceregene: R&D Pipeline, 2012

Table 5.7 BHR Pharma: R&D Pipeline, 2012

Table 5.8 Varinel: R&D Pipeline, 2012

Table 5.9 Varinel: Strategic Collaborations, 2012

Table 5.10 NINDS: Ongoing Clinical Trials, 2012

Table 6.1 Selected Neuroprotective Agents under Investigation for Brain Injury, 2012

Table 6.2 Selected Neuroprotective Agents under Investigation for Alzheimer's Disease, 2012

Table 6.3 Selected Neuroprotective Agents under Investigation for Parkinson's Disease, 2012

Table 6.4 Selected Neuroprotective Agents under Investigation for Multiple Sclerosis, 2012

Table 6.5 Selected Neuroprotective Agents under Investigation for Ocular Degeneration, 2012

Table 6.6 Selected Neuroprotective Agents under Investigation for Other Neurodegenerative Diseases, 2012

Table 7.1 Neuroprotective Agents Market: SWOT Analysis, 2012-2022

Table 7.2 Neuroprotective Agents Market: STEP Analysis, 2012-2022

Table 7.3 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050

Table 9.1 Key Neuroprotective Agents: Sales (\$bn) and Market Shares (%), 2022

## List Of Figures

### LIST OF FIGURES

Figure 3.1 Neuroprotective Agents World Market Forecast (\$bn), 2011-2022  
Figure 3.2 Neuroprotective Agents Market Shares (%) by Drug Categories, 2011  
Figure 3.3 Neuroprotective Agents Market Shares (%) by Drug Categories, 2015  
Figure 3.4 Neuroprotective Agents Market Shares (%) by Drug Categories, 2022  
Figure 3.5 Ion Channel Modulators Sales Forecast (\$bn), 2011-2022  
Figure 3.6 Mitochondrial Dysfunction Regulators Sales Forecast (\$bn), 2011-2022  
Figure 3.7 Anti-inflammatory & Anti-apoptotic Agents Forecast (\$bn), 2011-2022  
Figure 3.8 Neurotrophic Factors Forecast (\$bn), 2011-2022  
Figure 3.9 Other Neuroprotective Agents Forecast (\$bn), 2011-2022  
Figure 4.1 Rasagiline Sales Forecast (\$bn), 2011-2022  
Figure 4.2 Minocycline Sales Forecast (\$bn), 2011-2022  
Figure 4.3 Memantine Sales Forecast (\$bn), 2011-2022  
Figure 4.4 NeuroSTAT Sales Forecast (\$bn), 2011-2022  
Figure 4.5 Erythropoietin Sales Forecast (\$bn), 2011-2022  
Figure 4.6 GM6 Sales Forecast (\$bn), 2011-2022  
Figure 4.7 NNZ-2566 Sales Forecast (\$bn), 2011-2022  
Figure 4.8 Progesterone Sales Forecast (\$bn), 2011-2022  
Figure 4.9 Davunetide Sales Forecast (\$bn), 2011-2022  
Figure 4.10 Laquinimod Sales Forecast (\$bn), 2011-2022  
Figure 4.11 CXB909 Sales Forecast (\$bn), 2011-2022  
Figure 7.1 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050  
Figure 9.1 Key Neuroprotective Agents: Market Shares (%), 2022

### COMPANIES LISTED

Acorda Therapeutics  
Active Biotech AB  
Advancell  
Albert Einstein College of Medicine of Yeshiva University  
Alcon Laboratories  
Allergan  
Allon Therapeutics  
Alta Partners  
Alzheimer's Drug Discovery Foundation  
Alzheimer's Association

Alzheimer's Disease Cooperative Study (ADCS)  
American Brain Injury Consortium (ABIC)  
Arbor Vita Corporation  
Assistance Publique - Hôpitaux de Paris  
AstraZeneca  
Avraham Pharmaceuticals  
Bagcilar Training and Research Hospital  
Bastyr University  
Bayer  
Baylor College of Medicine  
Besins Healthcare  
BHR Pharma  
BioAxone Therapeutic  
Biogen Idec  
BioSante Pharmaceuticals  
Brain Cells  
BrainStorm Cell Therapeutics  
Buck Institute for Research on Aging  
Buck Institute of Technology  
Buddhist Tzu Chi General Hospital  
Cantonal Hospital of St. Gallen  
CAS Medical Systems  
Catholic University of the Sacred Heart  
CeNeRx BioPharma  
Centre Hospitalier Universitaire de Nice  
Ceregene  
Charité University  
CHDI  
Children's Hospital & Research Center Oakland  
Children's Hospital of Pittsburgh  
China Medical University Hospital  
Cornell University  
Daiichi Sankyo  
Danube Pharmaceuticals  
DENSMORE Pharmaceutical  
Department of Veterans Affairs  
Duke University  
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez  
Eli Lilly

EMD Serono  
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)  
European Brain Injury Consortium  
European Cooperative Network for Research, Diagnosis and Therapy of Parkinson's Disease  
Eyetechn  
Food and Drug Administration (US FDA)  
Forest Laboratories  
Fundacion para la Investigacion Biomedica del Hospital  
Genervon Biopharmaceuticals  
GW Pharmaceuticals  
Hadassah Medical Organization  
Hamilton BioVentures  
High Q Foundation  
Hoag Memorial Hospital Presbyterian  
Huntington Hospital  
Huntington Medical Research Institutes  
INC Research  
Institute for Quality and Efficiency in Health Care (IQWiG)  
Investor Growth Capital  
Janssen  
Jaslok Hospital and Research Centre  
Krenitsky Pharmaceuticals  
Laerdal Medical  
Lundbeck  
Max Planck Institute  
Medical University of South Carolina  
Merz Pharmaceuticals  
Michael J. Fox Foundation for Parkinson's Research  
Mount Sinai School of Medicine  
MPM Capital  
Multiple Sclerosis Society of Great Britain and Northern Ireland  
Multiple Sclerosis Trust  
Mylan  
National Center for Complementary and Alternative Medicine (NCCAM)  
National Heart, Lung, and Blood Institute (NHLBI)  
National Institute for Health and Clinical Excellence (NICE)  
National Institute of Neurological Disorders and Stroke (NINDS)

National Institute on Aging (NIA)  
National Institutes of Health (NIH)  
National Institutes of Health Clinical Center (CC)  
National Multiple Sclerosis Society  
Neuralstem  
Neuregenix  
Neuren Pharmaceuticals  
Neurological Emergencies Treatment Trials Network (NETT)  
Neuroscience Canada  
Neurotec Pharma  
Neurotech  
NeuroVive Pharmaceutical AB  
Newron Pharmaceuticals  
NoNO  
Northwestern University  
Novartis  
Office of Dietary Supplements (ODS)  
Ono Pharmaceutical  
Opexa Therapeutics  
Oregon Health and Science University  
Orion Pharma  
Oxygen Biotherapeutics  
Pfizer  
Pharmanza Herbal  
PRA International  
Prana Biotechnology  
QLT  
Quark Pharmaceuticals  
Rexahn Pharmaceuticals  
Roche  
Royan Institute  
Rush University Medical Center  
S & T Global  
Sanofi  
Santa Clara Valley Health & Hospital System  
Selcia  
Shaheed Beheshti Medical University  
SK Biopharmaceuticals  
StoneBridge Pharma

TCA Cellular Therapy  
Technion Medical School  
Teva Pharmaceutical Industries  
Texas Children's Hospital  
The Dana Foundation  
Thrasher Research Fund  
to-BBB  
Toyama Chemical Co.  
Universitaria Meyer  
Universitaria Pisana  
Universitario Ramon y Cajal  
University College London  
University of Calgary  
University of California, Los Angeles  
University of California, San Francisco  
University of Miami  
University of Rochester  
University of South Florida  
University of Utah  
University of Washington  
Varinel  
Verdure Sciences  
U.S. Department of Defense  
Watson Pharmaceuticals  
World Health Organization (WHO)  
Xuanwu Hospital, Beijing  
Zambon Company



## I would like to order

Product name: Neuroprotective Products: World Market Prospects 2012-2022

Product link: <https://marketpublishers.com/r/N0C4705368BEN.html>

Price: US\$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N0C4705368BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970